New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by

Pfizer licenses neratinib to newly created Puma Biotechnology
04 Sep 2018
Executive Summary
Cancer-focused start-up Puma Biotechnology Inc. has picked up its first compound by licensing worldwide development and commercialization rights to Pfizer Inc.’s neratinib, a Phase III tyrosine kinase inhibitor for HER2-positive breast cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com